09:00 AM EST, 11/07/2025 (MT Newswires) -- Atea Pharmaceuticals ( AVIR ) said Friday that new modelling data support the fixed-dose combination of bemnifosbuvir and ruzasvir to treat Hepatitis C.

The company said the combination reached near-complete inhibition of viral replication and assembly, and secretion into the bloodstream, with a time to cure of approximately seven to eight weeks.

The data will be presented at the annual meeting of the American Association for the Study of Liver Diseases, which is taking place from Nov. 7 to Nov. 11 in Washington, DC, the company said.

Shares of Atea Pharmaceuticals ( AVIR ) were down 1.2% in recent premarket activity.